Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706107 | 0.77 | CA4 (0.37) | LTA4HTSHR | |
| SCHEMBL5008068 | 0.68 | GSK3B (0.45) | — | |
| SCHEMBL9481670 | 0.68 | ALDH1A1 (0.44) | TSHRSMN1; SMN2 | |
| SCHEMBL10516808 | 0.67 | MAPK1 (0.37) | — | |
| SCHEMBL5232509 | 0.66 | LTA4H (0.36) | LTA4HTSHRTTRPPARGPPARA | |
| SCHEMBL705887 | 0.66 | MAPK1 (0.36) | LTA4H | |
| SCHEMBL713132 | 0.65 | RELA (0.33) | LTA4HTSHR | |
| SCHEMBL704633 | 0.64 | MAPK1 (0.34) | TSHR | |
| SCHEMBL3271153 | 0.64 | CYP4F2 (0.61) | LTA4HTSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL21228666 | 0.64 | PDK1 (0.32) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403250-B1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1403250-A1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | H1-0, BRD4, PAH | LTA4H 4525/4885TSHR 3525/4885TTR 868/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | LTA4H 4213/4885TSHR 1717/4885TTR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.